Biodesix, Inc. (BDSX)

NASDAQ: BDSX · IEX Real-Time Price · USD
2.61
+0.02 (0.77%)
At close: Aug 12, 2022 4:00 PM
2.56
-0.05 (-1.92%)
After-hours: Aug 12, 2022 4:07 PM EDT
0.77%
Market Cap 104.35M
Revenue (ttm) 31.25M
Net Income (ttm) -56.21M
Shares Out 39.98M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,988
Open 2.55
Previous Close 2.59
Day's Range 2.50 - 2.66
52-Week Range 1.25 - 10.22
Beta n/a
Analysts Buy
Price Target 6.12 (+134.5%)
Earnings Date Aug 4, 2022

About BDSX

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer t... [Read more...]

Industry Diagnostics & Research
IPO Date Oct 28, 2020
Employees 218
Stock Exchange NASDAQ
Ticker Symbol BDSX
Full Company Profile

Financial Performance

In 2021, Biodesix's revenue was $54.51 million, an increase of 19.64% compared to the previous year's $45.56 million. Losses were -$43.16 million, 37.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for BDSX stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 134.48% from the latest price.

Price Target
$6.12
(134.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biodesix Named a Top 100 Healthcare Technology Company of 2022

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been reco...

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 14.89% and 28.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Biodesix Announces Second Quarter 2022 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial an...

Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Ch...

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progr...

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang...

Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will rel...

Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the ...

Biodesix Announces Research Agreement with Top US Cancer Center

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel mi...

Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of ...

Biodesix to Present at the H.C. Wainwright Global Investment Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Ch...

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at A...

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impa...

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biodesix Announces First Quarter 2022 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for f...

Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will rel...

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 6,508,376 common shares on April 7,...

Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical I...

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that new data we...

Here's Why Biodesix, Inc. (BDSX) Looks Ripe for Bottom Fishing

Biodesix, Inc. (BDSX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among W...

Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial an...

Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out for

Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered i...

Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of L...

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data o...

Biodesix to Present at Cowen's 42nd Annual Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Ch...

Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will rel...

Biodesix CEO Scott Hutton Named to The Healthcare Technology Report's List of Top 25 Biotech CEOs in 2022

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that its Chief Ex...